Claudio Miguel Costa-Neto

Claudio Miguel Costa-Neto

Auto-generated profile, based on publicly available information

Claudio Miguel Costa-Neto

Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirao Preto, University of Sao Paulo, 14049-900 Ribeirao Preto, SP, Brazil

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2000 in Nature
Verified
Journal Article
Closed access
PDF file
ASA. J. G. Simpson
A. J. G. Simpson
FRF.C. Reinach
F.C. Reinach
PAP. Arruda
P. Arruda
FAF. A. Abreu
F. A. Abreu
MAMarcio Acencio
Marcio Acencio
JSJ. C. Setubal
J. C. Setubal

1 September 2007 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
SAS.M. Alencar
S.M. Alencar
Tatiane Luiza Cadorin OldoniTatiane Luiza Cadorin Oldoni
Tatiane Luiza Cadorin Oldoni
MCM.L. Castro
M.L. Castro
ICI.S.R. Cabral
I.S.R. Cabral
CCC.M. Costa-Neto
C.M. Costa-Neto
MIM. Ikegaki
M. Ikegaki

4 December 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
YNYoon Namkung
Yoon Namkung
CLChristian LeGouill
Christian LeGouill
SKSahil Kumar
Sahil Kumar
YCYubo Cao
Yubo Cao
LTLarissa B. Teixeira
Larissa B. Teixeira
SLStephane A Laporte
Stephane A Laporte
G protein–coupled receptors (GPCRs) are important therapeutic targets that exhibit functional selectivity (biased signaling), in which different ligands or receptor variants elicit distinct downstream signaling. Understanding all the signaling events and biases that contribute to both the beneficial and adverse effects of GPCR stimulation by given ligands is important for drug discovery. Here, we report the design, validation, and use of pathway-selective bioluminescence resonance energy transfer (BRET) biosensors that monitor the engagement and activation of signaling effectors downstream of G proteins, including protein kinase C (PKC), phospholipase C (PLC), p63RhoGEF, and Rho. Combined with G protein and β-arrestin BRET biosensors, our sensors enabled real-time monitoring of GPCR signaling at different levels in downstream pathways in both native and engineered cells. Profiling of the responses to 14 angiotensin II (AngII) type 1 receptor (AT1R) ligands enabled the clustering of compounds into different subfamilies of biased ligands and showed that, in addition to the previously reported functional selectivity between Gαq and β-arrestin, there are also biases among G protein subtypes. We also demonstrated that biases observed at the receptor and G protein levels propagated to downstream signaling pathways and that these biases could occur through the engagement of different G proteins to activate a common effector. We also used these tools to determine how naturally occurring AT1R variants affected signaling bias. This suite of BRET biosensors provides a useful resource for fingerprinting biased ligands and mutant receptors and for dissecting functional selectivity at various levels of GPCR signaling.

1 September 2006 in Phytochemistry
Verified
Journal Article
Closed access
GSGeraldo Humberto Silva
Geraldo Humberto Silva
HTHelder Lopes Teles
Helder Lopes Teles
LZLisinéia Maria Zanardi
Lisinéia Maria Zanardi
MYMaria Cláudia Young
Maria Cláudia Young
MEMarcos Nogueira Eberlin
Marcos Nogueira Eberlin
AAAngela Regina Araujo
Angela Regina Araujo

1 November 2016 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
CCClaudio M. Costa-Neto
Claudio M. Costa-Neto
LPLucas T. Parreiras-E-Silva
Lucas T. Parreiras-E-Silva
MBMichel Bouvier
Michel Bouvier
![Figure][1] When studying G protein–coupled receptor (GPCR) signaling and ligand-biased agonism, at least three dimensional spaces must be considered, as follows: 1) the distinct conformations that can be stabilized by different ligands promoting the engagement of different signaling effectors and accessory regulators; 2) the distinct subcellular trafficking that can be conferred by different ligands, which results in spatially distinct signals; and 3) the differential binding kinetics that maintain the receptor in specific conformation and/or subcellular localization for different periods of time, allowing for the engagement of distinct signaling effector subsets. These three pluridimensional aspects of signaling contribute to different faces of functional selectivity and provide a complex, interconnected way to define the signaling profile of each individual ligand acting at GPCRs. In this review, we discuss how each of these aspects may contribute to the diversity of signaling, but also how they shed light on the complexity of data analyses and interpretation. The impact of phenotype variability as a source of signaling diversity, and the influence of novel and more sensitive assays in the detection and analysis of signaling pluridimensionality, is also discussed. Finally, we discuss perspectives for the use of the concept of pluridimensional signaling in drug discovery, in which we highlight future predictive tools that may facilitate the identification of compounds with optimal therapeutic and safety properties based on the signaling signatures of drug candidates. [1]: pending:yes

19 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LTLarissa B. Teixeira
Larissa B. Teixeira
LPLucas T. Parreiras-E-Silva
Lucas T. Parreiras-E-Silva
TBThiago Bruder-Nascimento
Thiago Bruder-Nascimento
DDDiego A. Duarte
Diego A. Duarte
SSSarah C. Simões
Sarah C. Simões
CCClaudio M. Costa-Neto
Claudio M. Costa-Neto
The renin-angiotensin system (RAS) plays a key role in the control of vasoconstriction as well as sodium and fluid retention mediated mainly by angiotensin (Ang) II acting at the AT1receptor (AT1R). Ang-(1-7) is another RAS peptide, identified as the endogenous ligand of the Mas receptor and known to counterbalance many of the deleterious effects of AngII. AT1R signaling triggered by β-arrestin-biased agonists has been associated to cardioprotection. Because position 8 in AngII is important for G protein activation, we hypothesized that Ang-(1-7) could be an endogenous β-arrestin-biased agonist of the AT1R. Here we show that Ang-(1-7) binds to the AT1R without activating Gq, but triggering β-arrestins 1 and 2 recruitment and activation. Using anin vivomodel of cardiac hypertrophy, we show that Ang-(1-7) significantly attenuates heart hypertrophy by reducing both heart weight and ventricular wall thickness and the increased end-diastolic pressure. Whereas neither the single blockade of AT1or Mas receptors with their respective antagonists prevented the cardioprotective action of Ang1-7, combination of the two antagonists partially impaired the effect of Ang-(1-7). Taken together, these data indicate that Ang-(1-7) mediates at least part of its cardioprotective effects by acting as an endogenous β-arrestin-biased agonist at the AT1R.